A breakthrough in Multi–Cancer Early Detection

Spot early signals of 5-10(*) common and aggressive cancers using next generation of ctDNA technology

(*) The number of cancer types varies based on availability in different countries.

What is the
SPOT-MAS test?

SPOT-MAS is a non-invasive, multi-cancer early detection (MCED) test that detects tumor DNA (ctDNA) circulating in the blood. This test incorporates next-generation sequencing (NGS) and AI technologies to analyze the methylation profile and multiple features of ctDNA, enabling early detection for the 10 most common and aggressive cancers(*) from a single tube of blood.

(*) WHO GLOBOCAN South-East Asia Report, 2022
Find out:

Who is SPOT-MAS for?

The SPOT-MAS test is recommended for use in adults with elevated risk of cancer, such as those aged 40 years or older, those who carry genetic mutations, or those with unhealthy habits like smoking, drinking alcohol, getting hepatitis B, C. SPOT-MAS is not recommended for pregnant women or patients undergoing cancer treatment, or those with the history of bone marrow transplant, blood transfusion within 3 months.

Patients

  • Adults aged 
less than 40 years 
but have high risks
  • Adults aged
40 years & older

Healthcare Providers

  • Healthcare expert
  • Genetic specialist

Patients

Icon

Patient Guiding Handbook 11.40 MB 253 downloads

Spot early signals of 10 common and aggressive cancers using next generation of ctDNA...
Find out:

Healthcare Providers

Icon

Patient Guiding Handbook for Healthcare Professionals 19.45 MB 235 downloads

Spot early signals of common and aggressive cancers using next-generation of ctDNA...
Find out:

SPOT-MAS video